What is the recommended hemoglobin A1c target level for patients with CKD according to NKF KDOQI guidelines?

What is the recommended hemoglobin A1c target level for patients with CKD according to NKF KDOQI guidelines?

• A. 5%
• B. 7%
• C. 9%
• D. 11%

Answer: (B)

The recommended hemoglobin A1c target level for patients with chronic kidney disease (CKD) according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF KDOQI) guidelines is set at 7%. This target is significant for managing diabetes in patients with CKD, as it aims to balance effective glycemic control while minimizing the risk of complications associated with tight glucose control, such as hypoglycemia. Achieving an A1c level around 7% helps reduce the risk of both microvascular and macrovascular complications related to diabetes without increasing the risks that can particularly affect CKD patients, who may be more susceptible to adverse effects from intensive glucose-lowering therapies. Therefore, the 7% target strikes a practical compromise between the need for metabolic control and the safety considerations for this patient population. This approach aligns with a patient-centered focus, considering the unique challenges faced by individuals with CKD, such as the effects of diabetic treatment on kidney function and overall health.

The recommended hemoglobin A1c target level for patients with chronic kidney disease (CKD) according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF KDOQI) guidelines is set at 7%. This target is significant for managing diabetes in patients with CKD, as it aims to balance effective glycemic control while minimizing the risk of complications associated with tight glucose control, such as hypoglycemia.

Achieving an A1c level around 7% helps reduce the risk of both microvascular and macrovascular complications related to diabetes without increasing the risks that can particularly affect CKD patients, who may be more susceptible to adverse effects from intensive glucose-lowering therapies. Therefore, the 7% target strikes a practical compromise between the need for metabolic control and the safety considerations for this patient population. This approach aligns with a patient-centered focus, considering the unique challenges faced by individuals with CKD, such as the effects of diabetic treatment on kidney function and overall health.